|
1
|
Hu J, Qiu M, Jiang F, Zhang S, Yang X,
Wang J, Xu L and Yin R: MiR-145 regulates cancer stem-like
properties and epithelial-to-mesenchymal transition in lung
adenocarcinoma-initiating cells. Tumour Biol. 35:8953–8961. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Mariotto AB, Noone AM, Howlader N, Cho H,
Keel GE, Garshell J, Woloshin S and Schwartz LM: Cancer survival:
An overview of measures, uses, and interpretation. J Natl Cancer
Inst Monogr. 2014:145–186. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Johnson DH, Schiller JH and Bunn PA Jr:
Recent clinical advances in lung cancer management. J Clin Oncol.
32:973–982. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Tian L, Shen D, Li X, Shan X, Wang X, Yan
Q and Liu J: Ginsenoside Rg3 inhibits epithelial-mesenchymal
transition (EMT) and invasion of lung cancer by down-regulating
FUT4. Oncotarget. 7:1619–1632. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Bartis D, Mise N, Mahida RY, Eickelberg O
and Thickett DR: Epithelial-mesenchymal transition in lung
development and disease: Does it exist and is it important? Thorax.
69:760–765. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Yuan X, Wu H, Han N, Xu H, Chu Q, Yu S,
Chen Y and Wu K: Notch signaling and EMT in non-small cell lung
cancer: Biological significance and therapeutic application. J
Hematol Oncol. 7:872014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Mateen S, Raina K, Agarwal C, Chan D and
Agarwal R: Silibinin synergizes with histone deacetylase and DNA
methyltransferase inhibitors in upregulating E-cadherin expression
together with inhibition of migration and invasion of human
non-small cell lung cancer cells. J Pharmacol Exp Ther.
345:206–214. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Qu MH, Han C, Srivastava AK, Cui T, Zou N,
Gao ZQ and Wang QE: miR-93 promotes TGF-β-induced
epithelial-to-mesenchymal transition through downregulation of
NEDD4L in lung cancer cells. Tumour Biol. 37:5645–5651. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Wang LK, Pan SH, Chang YL, Hung PF, Kao
SH, Wang WL, Lin CW, Yang SC, Liang CH, Wu CT, et al:
MDA-9/Syntenin-Slug transcriptional complex promote
epithelial-mesenchymal transition and invasion/metastasis in lung
adenocarcinoma. Oncotarget. 7:386–401. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Qu J, Li M, An J, Zhao B, Zhong W, Gu Q,
Cao L, Yang H and Hu C: MicroRNA-33b inhibits lung adenocarcinoma
cell growth, invasion, and epithelial-mesenchymal transition by
suppressing Wnt/β-catenin/ZEB1 signaling. Int J Oncol.
47:2141–2152. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kim J, Moon SH, Kim BT, Chae CH, Lee JY
and Kim SH: A novel aminothiazole KY-05009 with potential to
inhibit Traf2- and Nck-interacting kinase (TNIK) attenuates
TGF-β1-mediated epithelial-to-mesenchymal transition in human lung
adenocarcinoma A549 cells. PLoS One. 9:e1101802014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Ebrahimi A and Sadroddiny E: MicroRNAs in
lung diseases: Recent findings and their pathophysiological
implications. Pulm Pharmacol Ther. 34:55–63. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Feng B, Zhang K, Wang R and Chen L:
Non-small-cell lung cancer and miRNAs: Novel biomarkers and
promising tools for treatment. Clin Sci (Lond). 128:619–634. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Xia W, Chen Q, Wang J, Mao Q, Dong G, Shi
R, Zheng Y, Xu L and Jiang F: DNA methylation mediated silencing of
microRNA-145 is a potential prognostic marker in patients with lung
adenocarcinoma. Sci Rep. 5:169012015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ju BL, Chen YB, Zhang WY, Yu CH, Zhu DQ
and Jin J: miR-145 regulates chemoresistance in hepatocellular
carcinoma via epithelial mesenchymal transition. Cell Mol Biol
(Noisy-le-grand). 61:12–16. 2015.PubMed/NCBI
|
|
16
|
Tan J, Qiu K, Li M and Liang Y:
Double-negative feedback loop between long non-coding RNA TUG1 and
miR-145 promotes epithelial to mesenchymal transition and
radioresistance in human bladder cancer cells. FEBS Lett.
589:3175–3181. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zhang Y, Yang X, Wu H, Zhou W and Liu Z:
MicroRNA-145 inhibits migration and invasion via inhibition of
fascin 1 protein expression in non-small-cell lung cancer cells.
Mol Med Rep. 12:6193–6198. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Ye Z, Shen N, Weng Y, Li K, Hu L, Liao H,
An J, Liu L, Lao S and Cai S: Low miR-145 silenced by DNA
methylation promotes NSCLC cell proliferation, migration and
invasion by targeting mucin 1. Cancer Biol Ther. 16:1071–1079.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Sahu SK, Garding A, Tiwari N, Thakurela S,
Toedling J, Gebhard S, Ortega F, Schmarowski N, Berninger B, Nitsch
R, et al: JNK-dependent gene regulatory circuitry governs
mesenchymal fate. EMBO J. 34:2162–2181. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ding H, Ji X, Chen R, Ma T, Tang Z, Fen Y
and Cai H: Antifibrotic properties of receptor for advanced
glycation end products in idiopathic pulmonary fibrosis. Pulm
Pharmacol Ther. 35:34–41. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Alizadeh AM, Shiri S and Farsinejad S:
Metastasis review: From bench to bedside. Tumour Biol.
35:8483–8523. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Guan X: Cancer metastases: Challenges and
opportunities. Acta Pharm Sin B. 5:402–418. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Qi D, Gill Kaur N, Santiskulvong C,
Sifuentes J, Dorigo O, Rao J, Taylor-Harding B, Wiedemeyer Ruprecht
W and Rowat AC: Screening cell mechanotype by parallel
microfiltration. Sci Rep. 5:175952015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zheng H and Kang Y: Multilayer control of
the EMT master regulators. Oncogene. 33:1755–1763. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Satelli A and Li S: Vimentin in cancer and
its potential as a molecular target for cancer therapy. Cell Mol
Life Sci. 68:3033–3046. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Zhou J, Wang J, Zeng Y, Zhang X, Hu Q,
Zheng J, Chen B, Xie B and Zhang WM: Implication of
epithelial-mesenchymal transition in IGF1R-induced resistance to
EGFR-TKIs in advanced non-small cell lung cancer. Oncotarget.
29:44332–44345. 2015. View Article : Google Scholar
|
|
28
|
Yao Y, Shi M, Liu S and Li Y, Guo K, Ci Y,
Liu W and Li Y: MARVELD1 modulates cell surface morphology and
suppresses epithelial-mesenchymal transition in non-small cell lung
cancer. Mol Carcinog. 55:1714–1727. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Zhao Q, Yue J, Zhang C, Gu X, Chen H and
Xu L: Inactivation of M2 AChR/NF-κB signaling axis reverses
epithelial-mesenchymal transition (EMT) and suppresses migration
and invasion in non-small cell lung cancer (NSCLC). Oncotarget.
6:29335–29346. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Ding W, Tan H, Zhao C, Li X, Li Z, Jiang
C, Zhang Y and Wang L: MiR-145 suppresses cell proliferation and
motility by inhibiting ROCK1 in hepatocellular carcinoma. Tumour
Biol. 37:6255–6260. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Chen B, Huang Z, Zhang Y, Chen Y and Li Z:
MicroRNA-145 suppresses osteosarcoma metastasis via targeting
MMP16. Cell Physiol Biochem. 37:2183–2193. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Li YQ, He QM, Ren XY, Tang XR, Xu YF, Wen
X, Yang XJ, Ma J and Liu N: MiR-145 inhibits metastasis by
targeting fascin actin-bundling protein 1 in nasopharyngeal
carcinoma. PLoS One. 10:e01222282015. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Wang M, Wang J, Deng J, Li X, Long W and
Chang Y: MiR-145 acts as a metastasis suppressor by targeting
metadherin in lung cancer. Med Oncol. 32:3442015. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Wang Z, Ma B, Li H, Xiao X, Zhou W, Liu F,
Zhang B, Zhu M, Yang Q and Zeng Y: Protein 4.1 acts as a potential
tumor suppressor linking PP1 to JNK-c-Jun pathway regulation in
NSCLC. Oncotarget. 7:509–523. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Lo Iacono M, Monica V, Vavalà T, Gisabella
M, Saviozzi S, Bracco E, Novello S, Papotti M and Scagliotti GV:
ATF2 contributes to cisplatin resistance in non-small cell lung
cancer and celastrol induces cisplatin resensitization through
inhibition of JNK/ATF2 pathway. Int J Cancer. 136:2598–2609. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Song W, Ma Y, Wang J, Brantley-Sieders D
and Chen J: JNK signaling mediates EPHA2-dependent tumor cell
proliferation, motility, and cancer stem cell-like properties in
non-small cell lung cancer. Cancer Res. 74:2444–2454. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Luo XJ, Liu B, Dai Z, Li TB, Li NS, Zhang
XJ, Yang ZC, Li YJ and Peng J: Expression of apoptosis-associated
microRNAs in ethanol-induced acute gastric mucosal injury via JNK
pathway. Alcohol. 47:481–493. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Chen R, Chen S, Liao J, Chen X and Xu X:
MiR-145 facilitates proliferation and migration of endothelial
progenitor cells and recanalization of arterial thrombosis in
cerebral infarction mice via JNK signal pathway. Int J Clin Exp
Pathol. 8:13770–13776. 2015.PubMed/NCBI
|
|
39
|
Hu P, Huang Q, Li Z, Wu X, Ouyang Q, Chen
J and Cao Y: Silencing MAP3K1 expression through RNA interference
enhances paclitaxel-induced cell cycle arrest in human breast
cancer cells. Mol Biol Rep. 41:19–24. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Wei X, Zhang E, Wang C, Gu D, Shen L, Wang
M, Xu Z, Gong W, Tang C, Gao J, et al: A MAP3k1 SNP predicts
survival of gastric cancer in a Chinese population. PLoS One.
9:e960832014. View Article : Google Scholar : PubMed/NCBI
|
